Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

Dykema adds senior counsel to IP team
Pharma
Dykema adds senior counsel to IP team
ANDA litigation expert brings chemical, biotech, and pharmaceutical experience to the firm.   26 September 2023
Yale University settles royalty dispute with US government
Americas
Yale University settles royalty dispute with US government
Agreement reached over intranasal ketamine royalties and patents | Yale and a professor agree to pay $1.5m to the US government and give up royalty rights.   26 September 2023
US Court of Appeals sides with Apple in Masimo dispute
Pharma
US Court of Appeals sides with Apple in Masimo dispute
Court upholds USPTO and the PTAB decisions over blood-oxygen sensor in smartwatches | Ruling finds Masimo patents to be unpatentable and obvious | Only one claim relating to inconsistency to be reversed.   14 September 2023
Biotech
UN race committee says global north’s COVID-19 IP position violates human rights
UN Committee on Racial Discrimination Calls for equitable access to vaccines, treatments, and health tech | Switzerland, Germany, UK, and US refusal to waive IP rights for COVID-19 vaccines 'aids discrimination against vulnerable communities'.   5 September 2023
Pharma
UPC announces hearing details for Edwards Lifesciences
Edwards Lifesciences files application for provisional measures at UPC | Hearing details adds to existing listed by the court for 10x Genomics versus NanoString.   31 August 2023
Pharma
BioNTech and Pfizer challenge Moderna’s COVID-19 vaccine patent
Inter partes review challenges broad claims and monopolisation over mRNA tech amidst existing legal dispute | Alnylam set to appeal separate court ruling against Moderna.   29 August 2023
Pharma
Pharma companies pay £255m to settle price-fixing charges
Payments mark the sixth and seventh made to resolve price-fixing charges | Teva donates $50 million in drugs to humanitarian organisations.   24 August 2023
Pharma
Foley Hoag adds partner in Boston
Biologics patent attorney aims to strengthen the firm’s global patent networks.   22 August 2023
Pharma
Indivior parts with $30m in Suboxone dispute
The pharmaceutical company agreed to pay millions to resolve a multi-district antitrust suit brought by more than 40 US state attorneys | Company sued over alleged actions aimed at preserving the monopoly of anti-addiction drug.   22 August 2023
Pharma
Endo sues Indian drug maker over anti-smoking drug patent
Patent-in-suit relates to a synthetic drug used to treat nicotine dependence | Development comes after USFood and Drug Administration sets new guidelines forcing the withdrawal of another big pharma firm’s rival drug.   10 August 2023

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.